CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

2024-518362-27-00 Protocol IC 2018-06 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 18 May 2021 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol IC 2018-06

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 101
Countries 1
Sites 4

Patients with recurrent and/or metastatic solid cancer.

Key facts

Sponsor
Institut Curie
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
18 May 2021 → ongoing
Decision date (initial)
2024-11-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518362-27-00
EudraCT number
2020-003599-42

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with recurrent and/or metastatic solid cancer.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Curie

Sponsor organisation
Institut Curie
Address
26 Rue D Ulm
City
Paris
Postcode
75005
Country
France

Scientific contact point

Organisation
Institut Curie
Contact name
Marie-Paule Sablin

Public contact point

Organisation
Institut Curie
Contact name
Marie-Paule Sablin

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 101 4
Rest of world 0

Investigational sites

France

4 sites · Ongoing, recruiting
Institut Gustave Roussy
Oncologie médicale - essais précoces, 114 Rue Edouard Vaillant, 94800, Villejuif
Institut De Cancerologie De L Ouest
Oncologie médicale - essais précoces, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Institut Curie
Oncologie médicale - essais précoces, 26 Rue D Ulm, 75005, Paris
Centre Francois Baclesse
Oncologie médicale - essais précoces, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2021-05-18 2021-05-18

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-26 France Acceptable
2024-11-08
2024-11-08
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-05 France Acceptable 2025-01-14
3 SUBSTANTIAL MODIFICATION SM-2 2025-11-07 France Acceptable
2025-11-26
2025-11-28